Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
TAKEDA PHARMACEUTICAL CO LTD (CIK 1395064) reported $16.4M across 8 reported positions in its SEC 13F filing for 2025-09-30. Largest positions: OVID ($9.8M, 59.82%), EQ ($2.6M, 15.94%), XLO ($1.2M, 7.59%), STTK ($1.2M, 7.53%), LYEL ($891,365, 5.45%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | OVID | Ovid Therapeutics, Inc. | $9.8M | 59.82% | 7.5M | Hold |
| 2 | EQ | Equillium, Inc. | $2.6M | 15.94% | 1.8M | Hold |
| 3 | XLO | Xilio Therapeutics, Inc. (formerly Akrevia Therapeutics) | $1.2M | 7.59% | 1.5M | Hold |
| 4 | STTK | Shattuck Labs, Inc. | $1.2M | 7.53% | 515,619 | Hold |
| 5 | LYEL | Lyell Immunopharma, Inc. | $891,365 | 5.45% | 54,887 | Added |
| 6 | AMWL | American Well Corporation | $478,061 | 2.92% | 77,733 | Hold |
| 7 | RANI | Rani Therapeutics Holdings, Inc. | $101,554 | 0.62% | 203,190 | Hold |
| 8 | LAB | Standard Biotools, Inc. | $21,470 | 0.13% | 16,515 | Hold |
| 9 | HLVX | HilleVax, Inc. | $0 | 0.00% | 0 | Exited |
| 10 | THRD | Third Harmonic Bio, Inc. | $0 | 0.00% | 0 | Exited |
| 11 | TSBX | Turnstone Biologics | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2025-09-30